Q linea AB. Stock Analysis QLINEA.ST

Q-linea AB operates as a holding company. The company employs 73 full-time employees The company went IPO on 2018-12-07. The firm develops and manufactures in-vitro diagnostic (IVD) solutions for infectious diseases. The firm's core product candidate is ASTar, a fully-automated instrument for Antibiotic Susceptibility Testing (AST). The company measures bacteria's antimicrobial susceptibility using the disposables developed by the Company. The company is able to provide a susceptibility profile within three to six hours directly from a positive blood culture, which enables early administration of antibiotics specifically targeting the disease-causing pathogen. Its main application is the identification of sepsis in hospital patients and the product is aimed primarily at hospital laboratories.